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Abstract
Background Hypoalbuminemia is a strong predictor of hospitalization and mortality among adult dialysis patients. However,
data are scant on the association between serum albumin and hospitalization among children new to dialysis.
Methods In a retrospective cohort study of children 1–17 years old with end-stage renal disease receiving dialysis therapy in a
large US dialysis organization 2007–2011, we examined the association of serum albumin with hospitalization frequency and
total hospitalization days using a negative binomial regression model.
Results Among 416 eligible patients, median (interquartile range) age was 14 (10–16) years and mean ± SD baseline serum
albumin level was 3.7 ± 0.8 g/dL. Two hundred sixty-six patients (64%) were hospitalized during follow-up with an incidence rate
of 2.2 (95%CI, 1.9–2.4) admissions per patient-year. There was a U-shaped association between serum albumin and hospitaliza-
tion frequency; hospitalization rates (95%CI) were 2.7 (2.2–3.2), 1.9 (1.5–2.4), 1.6 (1.3–1.9), and 2.7 (1.7–3.6) per patient-year
among patients with serum albumin levels < 3.5, 3.5– < 4.0, 4.0– < 4.5, and ≥ 4.5 g/dL, respectively. Case mix-adjusted hospital-
ization incidence rate ratios (IRRs) (95%CI) were 1.63 (1.24–2.13), 1.32 (1.10–1.58), and 1.25 (1.06–1.49) at serum albumin
levels 3.0, 3.5, and 4.5 g/dL, respectively (reference: 4.0 g/dL). Similar trends were observed in hospitalization days. These
associations remained robust against further adjustment for laboratory variables associated with malnutrition and inflammation.
Conclusions Both high and low serum albumin were associated with higher hospitalization in children starting dialysis. Because the
observed association is novel and not fully explainable especially for high serum albumin levels, interpreting the results requires
caution and further studies are needed to confirm and elucidate this association before clinical recommendations are made.
Keywords Hypoalbuminemia . Hyperalbuminemia . Hospitalization . Protein energywasting . Incident dialysis patients
Introduction
Serum albumin is a strong predictor for adverse outcomes
in adults with chronic kidney disease (CKD) [1].
Hypoalbuminemia may reflect poor nutrition, inflamma-
tion, or other systemic conditions associated with comor-
bidities [2]. Protein energy wasting (PEW) is common in
patients with CKD and associated with adverse clinical
outcomes [3]. PEW is closely associated with malnutrition
and inflammation, where serum albumin is an established
surrogate biomarker [4]. Children with CKD are also at
high risk of poor nutrition and chronic inflammation [5,
6]. Because these conditions are amenable to treatments,
recognition of hypoalbuminemia and underlying status
may improve patient management, potentially leading to
better clinical outcomes [7].
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Malnutrition and inflammation are associated with adverse
outcomes such as death or hospitalization [8, 9]. Furthermore,
among children with CKD, inadequate nutrition is one of the
most common causes of growth failure, resulting in short stat-
ure or low body mass index (BMI) [10], which is also associ-
ated with death or hospitalization [11–14]. Hypoalbuminemia
is known to be an independent predictor of survival and hos-
pitalization in adult patients with end-stage renal disease
(ESRD) on dialysis [15, 16]. In children with ESRD, a few
studies have focused on mortality or hospitalization as out-
comes, showing the association of hypoalbuminemia with
high mortality in incident dialysis patients [17] and high hos-
pitalization frequency in prevalent dialysis patients [18].
However, there are scarce data among pediatric patients new
to dialysis therapy for the association between serum albumin
and hospitalization. In addition, because previous studies have
placed a particular emphasis on hypoalbuminemia as a marker
of PEW, they estimated the association using two or three
albumin categories without consideration of all levels of se-
rum albumin. Thus, whether there is a non-linear association
of serum albumin with hospitalization in pediatric dialysis
patients is still unclear.
Therefore, we aimed to evaluate the association between
serum albumin and hospitalization over a wide range of serum
albumin levels among pediatric patients new to dialysis. We
also examined the cross-sectional association of serum albu-
min with height and BMI.
Methods
Information on death, hospitalization, race/ethnicity, insur-
ance, primary cause of ESRD, dialysis modality, comorbidi-
ties, medication, anthropometric data, and laboratory data was
obtained from a statistically de-identified data set derived
from the electronic database of the dialysis provider.
Patients
We retrospectively examined statistically de-identified data
from all incident hemodialysis (HD) and peritoneal dialysis
(PD) patients who were 1 to 17 years old and underwent
dialysis treatment in facilities operated by a large dialysis or-
ganization in the USA from January 1, 2007 to December 31,
2011. We excluded patients with missing serum albumin data
within 1 year from dialysis initiation, or were censored on the
same date of the index albumin measurement. Patients were
observed from the date of the first albumin measurement to
transplantation, lost to follow-up, discontinuation of dialysis,
or the end of follow-up (December 31, 2011), whichever oc-
curred first.
Demographic, clinical, and laboratory measures
Comorbidities were defined based on International
Classification of Diseases-9 (ICD-9) codes. Hypertension as
a comorbidity was also applied for patients having systolic
blood pressure ≥ 95th percentile at baseline [19].
Blood samples were drawn at the time of the clinic visit in
PD patients and before dialysis session in HD patients using
standardized techniques in all dialysis clinics and assayed typ-
ically within 24 hours of collection. All laboratory values were
measured by automated and standardized methods in the cen-
tral laboratory (Deland, FL). Serum albumin was measured
centrally using the bromocresol green method. To minimize
measurement variability, all repeated measures except serum
albumin were averaged for each patient during each 91 days
from dialysis initiation (i.e., patient-quarter), and the quarterly
means in each quarter were used in all analyses. The first
available serum albumin value after initiation of dialysis
served as baseline, while the quarterly averaged values during
the patient-quarter with the first available serum albumin draw
served as baseline for the other laboratory data. Most labora-
tory values such as albumin, calcium, phosphorus, creatinine,
and bicarbonate were measured monthly. Ferritin and intact
parathyroid hormone (iPTH) were measured at least quarterly.
Hemoglobin was measured weekly to biweekly in most
patients.
Hospitalization records
We excluded hospitalization records with a date of admission
prior to the index albumin measurement or after the censoring
date. We also excluded records with admission and discharge
on the same date, i.e., hospitalization was defined as a hospital
admission that included at least one overnight stay.
Hospitalizations likely related to kidney transplantation,
which were defined as any hospitalization including the date
of kidney transplantation, were also excluded. Previous dis-
charge and next admission on the same date were considered
as two distinct hospitalizations. For calculating hospitalization
days, the admission day was counted as one full hospitaliza-
tion day while the discharge day was not; one overnight stay
in hospital was regarded as a hospitalization for 1 day.
Height and BMI
We used data on height extracted in the same year as the index
albumin date and data on quarterly averaged body weight
obtained from the same patient-quarter as the first available
serum albumin. BMI was calculated using height and weight.
Height and BMI values were age and sex standardized to z
scores using the 2000 Centers for Disease Control and
Prevention (CDC) Growth Chart.
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Statistical analysis
Baseline characteristics are summarized with categorized se-
rum albumin level as < 3.5 g/dL, 3.5 to < 4.0 g/dL, 4.0 to <
4.5 g/dL, and ≥ 4.5 g/dL, and are expressed as numbers (pro-
portions), mean ± SD, or medians (interquartile range, IQR),
as appropriate.
We used a negative binomial regression model to eval-
uate the associations of baseline serum albumin with hos-
pitalization frequency and total hospitalization days be-
cause of overdispersion in the distribution of hospitaliza-
tion frequency and days. We examined the cause-specific
hospitalization as well as overall hospitalization in the hos-
pitalization frequency analysis. As sensitivity analyses,
baseline and time-dependent Cox regression models were
used for time to first hospitalization. Since serum albumin
levels may change within 1 year from dialysis initiation,
and may influence the association between baseline serum
albumin and hospitalization, we also examined the associ-
ation between serum albumin and hospitalization frequen-
cy among patients with baseline serum albumin obtained
within 3 months of dialysis initiation as a sensitivity anal-
ysis. Linear regression analysis was used to estimate the
association of serum albumin with z scores of height and
BMI. Results from negative binomial, Cox, and linear re-
gression models were expressed as incidence rate ratios
(IRRs), hazard ratios, and z score differences, respectively
(reference serum albumin 4.0 g/dL). Baseline and time-
varying serum albumin were also modeled as a continuous
variable, and their associations with outcomes were esti-
mated using restricted cubic spline functions with four
knots [20].
Each model, except analyses for height and BMI, was ex-
amined with four levels of adjustment, i.e., unadjusted, case
mix-adjusted, case mix plus height-adjusted, and a fully ad-
justed model which includes laboratory variables associated
with malnutrition and inflammation. Unadjusted models
consisted of baseline or time-varying albumin values. Case
mix-adjusted models included serum albumin values plus
age, sex, race/ethnicity (Caucasian, African American,
Hispanic, other races), primary insurance (Medicare,
Medicaid, other insurance), primary cause of ESRD (congen-
ital anomalies of the kidney and urinary tract, glomerulone-
phritis, other cause), dialysis type (HD, PD), access type (cen-
tral venous catheter, arteriovenous fistula [AVF], PD catheter),
dialysis vintage, transplantation prior to first dialysis date,
comorbidities (hypertension, cardiovascular disease, diabetes
mellitus, endocrine/metabolic disease, autoimmune disease),
and medication. For the case mix plus height-adjusted model,
height z score was added to covariates in the case mix model.
In fully adjusted models, we adjusted for all of the covariates in
the case mix model plus height, BMI, baseline or time-varying
hemoglobin, ferritin, iron saturation, albumin-corrected
calcium, phosphorus, iPTH, white blood cell count, bicarbon-
ate, and creatinine. We limited covariates to age, sex, and race/
ethnicity when analyzing the associations with height and BMI.
We examined potential modification of the association be-
tween baseline serum albumin and hospitalization frequency
by casemix variables, i.e., age, sex, race (African American or
non-African American), dialysis type (HD or PD), and cause
of ESRD (glomerulonephritis or not) by including each set of
their interaction terms with spline functions of baseline serum
albumin into regression models. Furthermore, we included all
interaction terms into regression models and used stepwise
backward selection for the interaction terms while retaining
all the other covariates. Because dialysis modality and cause
of ESRD are particularly important potential confounders and/
or effect modifiers of the association between serum albumin
and hospitalization, we performed subgroup analyses by dial-
ysis modality (HD or PD) and cause of ESRD (glomerulone-
phritis or not). In addition, we focused on patients 1–< 6 years
old and performed subgroup analysis by age (< 6 or ≥ 6 years)
because younger patients may have lower serum albumin and
high risk for hospitalization. We further conducted subgroup
analyses based on the results of the interaction tests.
The frequency of missing data was less than 10% in most
baseline variables, except for BMI (28%), and a multiple im-
putation method with 30 data sets was used for analyses.
Missing laboratory values in time-dependent analysis includ-
ing serum albumin were imputed with last observation carried
forward. There were 40missing values on serum albumin over
a total of 965 patient-quarters. Analyses were performed using
STATA MP, version 13.1 (Stata Corp, College Station, TX).
Results
Baseline characteristics
A total of 480 patients who initiated dialysis between 2007 and
2011 were identified. After excluding 4 patients who were cen-
sored on the same date as the index albumin measurement and
60 patients who had missing serum albumin data within 1 year
from dialysis initiation, the final cohort comprised 416 pediatric
dialysis patients (Fig. 1). In the final cohort, mean ± SD baseline
albumin level was 3.7 ± 0.8 g/dL, median (IQR) dialysis vin-
tage was 14 (6–40) days, andmedian (IQR) age was 14 (10–16)
years old. Patients with lower serum albumin levels had lower
levels of hemoglobin and serum creatinine (Table 1).
Hospitalization frequency, total hospitalization days,
and time to first hospitalization
Among 416 included patients, 266 patients were hospitalized
at least once within the observation period. The overall hos-
pitalization rate and hospitalization days were 2.2 (95%CI,
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1.9–2.4) and 12.7 (95%CI, 10.3–15.0) days per patient-year,
respectively. Patients with both lower and higher serum albu-
min appeared to have higher hospitalization rates and longer
hospitalization days (Table 2). Consistently, the IRRs were
higher for both lower and higher serum albumin, whereas
the lowest risk was observed in the ranges of serum albumin
levels 3.9–4.2 g/dL in the unadjusted, case mix-adjusted, case
mix plus height adjusted, and fully adjusted models (Figs. 2
and 3). In the case mix-adjusted model, IRRs for hospitaliza-
tion frequency were 1.63 (95%CI, 1.24–2.13), 1.32 (95%CI,
1.10–1.58), and 1.25 (95%CI, 1.06–1.49) at serum albumin
levels of 3.0 g/dL, 3.5 g/dL, and 4.5 g/dL, respectively (refer-
ence: 4.0 g/dL). Likewise, adjusted IRRs for total hospitaliza-
tion days were 2.06 (95%CI, 1.33–3.19), 1.48 (95%CI, 1.11–
1.99), and 1.39 (95%CI, 1.06–1.83) at 3.0 g/dL, 3.5 g/dL, and
4.5 g/dL, respectively. The leading causes of hospitalization
were infection (171 hospitalizations, 16%) and dialysis
access-related hospitalization (73 hospitalizations, 7%)
among a total of 1037 hospitalizations. In the case mix-
adjusted model for hospitalization frequency, IRRs for
infection-related hospitalization were 1.37 (95%CI, 0.79–
2.37), 1.34 (95%CI, 0.93–1.95), and 0.83 (95%CI, 0.55–
1.26); those for access-related hospitalization were 1.21
(95%CI, 0.58–2.52), 1.07 (95%CI, 0.66–1.74), and 1.32
(95%CI, 0.87–2.00) at serum albumin levels of 3.0 g/dL,
3.5 g/dL, and 4.5 g/dL, respectively (reference: 4.0 g/dL)
(Supplemental Fig. 1). The association between serum albu-
min and hospitalization frequency was consistent in the re-
stricted cohort of patients with baseline serum albumin obtain-
ed within 3 months of dialysis initiation (Supplemental
Fig. 2). In the sensitivity analysis using time to the first hos-
pitalization as the outcome, both baseline and time-dependent
Cox models showed consistent associations (Fig. 4,
Supplemental Fig. 3, Supplemental Table 1).
Subgroup analysis for hospitalization frequency
In subgroup analyses by age, dialysis modality, and cause of
ESRD, the association between serum albumin and
hospitalization frequency was consistent with the overall anal-
ysis in all of the subgroups (Supplemental Fig. 4–6).
Sex and race were potential effect modifiers on the
associations between serum albumin and hospitalization
frequency in the model including the respective interac-
tion term with serum albumin on top of case mix vari-
ables, as well as in the backward stepwise selection
models including all interaction terms of interest
(Pinteraction < 0.2 for both). Whereas males showed an
association consistent with the overall analysis, there
was no significant association with hospitalization fre-
quency over the observed range of serum albumin levels
among females (Fig. 5a, b). We further stratified sex and
race into 4 groups, i.e., African American male, African
American female, non-African American male, and non-
African American female. The associations observed in
male and female subgroups were consistent among non-
African American patients (Fig. 5c, d). We did not esti-
mate the association of serum albumin and hospitaliza-
tion for African American male and female groups due
to the small sample size.
Height and BMI
The analytical cohort for height included 401 patients
with available data. Mean ± SD z score was − 0.8 ± 1.5
and 81 patients (20%) were short stature, defined as a
height less than − 2.0 SD [21]. Both lower and higher
albumin levels were associated with lower z score in the
linear regression model (Fig. 6a). BMI data were avail-
able in 299 patients, and mean ± SD z score was 0.2 ±
1.4. Although BMI z score slightly decreased with higher
albumin level, there was no significant difference accord-
ing to serum albumin level overall (Fig. 6b).
Discussion
In this study of pediatric dialysis patients, baseline se-
rum albumin levels showed a U-shaped association with
hospitalization outcomes. A consistent association was
observed in the time-varying model. The association of
serum albumin with hospitalization frequency was mod-
ified by sex and race, and the hospitalization risk asso-
ciated with low and/or high serum albumin was drasti-
cally attenuated in female patients. Serum albumin also
showed a U-shaped association with height z score,
while there was no particular relationship between se-
rum albumin and BMI.
A U-shaped association between serum albumin and hos-
pitalization was consistent across all adjustment levels for
hospitalization frequency, total hospitalization days, and time
to first hospitalization using both baseline and time-varying
480 incident dialysis patients (1–17 years old)
between 2007 and 2011
4 children with starting observation and 
censoring on the same date
476
416 patients 
60 children with missing data on serum 
albumin within 1 year from dialysis initiation
Fig. 1 Cohort construction
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Table 1 Baseline characteristics by serum albumin levels
Total Baseline serum albumin level (g/dL)
< 3.5 3.5 to < 4.0 4.0 to < 4.5 ≥ 4.5
N (%) 416 130 (31) 108 (26) 121 (29) 57 (14)
Age (years) 14 (10–16) 13 (4–16) 15 (12–16) 15 (12–17) 14 (8–16)
< 6 years (%) 76 (18) 39 (30) 13 (12) 12 (10) 12 (21)
6 to < 13 years (%) 73 (18) 24 (18) 18 (17) 22 (18) ≤ 10
≥ 13 years (%) 267 (64) 67 (52) 77 (71) 87 (72) 36 (63)
Male (%) 225 (54) 71 (55) 47 (44) 71 (59) 36 (63)
Race/ethnicity (%)
Caucasian 160 (38) 53 (41) 36 (33) 48 (40) 23 (40)
African American 95 (23) 31 (24) 28 (26) 25 (21) 11 (19)
Hispanic 130 (31) 34 (26) 35 (32) 40 (33) 21 (37)
Other 31 (7) 12 (9) ≤ 10 ≤ 10 ≤ 10
Insurance (%)
Medicare 73 (18) 24 (18) 18 (17) 24 (20) ≤ 10
Medicaid 93 (22) 25 (19) 26 (24) 26 (21) 16 (28)
Other 250 (60) 81 (62) 64 (59) 71 (59) 34 (60)
Cause of ESRD (%)
CAKUT 95 (23) 25 (19) 23 (21) 33 (27) 14 (25)
Glomerulonephritis 133 (32) 57 (44) 33 (31) 34 (28) ≤ 10
Other 188 (45) 48 (37) 52 (48) 54 (45) 34 (60)
Dialysis type (%)
HD 232 (56) 64 (49) 68 (63) 71 (59) 29 (51)
PD 184 (44) 66 (51) 40 (37) 50 (41) 28 (49)
Access type (%)
CV catheter 208 (50) 63 (48) 61 (56) 57 (47) 27 (47)
AVF 24 (6) ≤ 10 ≤ 10 14 (12) ≤ 10
PD catheter 184 (44) 66 (51) 40 (37) 50 (41) 28 (49)
Dialysis vintage (days) 14 (6–40) 13 (4–28) 12 (6–29) 19 (7–59) 18 (7–42)
Height z score − 0.8 ± 1.5 − 0.9 ± 1.5 − 0.6 ± 1.5 − 0.7 ± 1.3 − 1.1 ± 1.6
BMI z score 0.2 ± 1.4 0.3 ± 1.3 0.3 ± 1.4 0.2 ± 1.4 0.0 ± 1.3
Hemoglobin (g/dL) 11.1 ± 1.5 10.7 ± 1.5 11.1 ± 1.5 11.2 ± 1.3 11.5 ± 1.6
Ferritin (ng/mL) 196 (99–397) 184 (110–377) 222 (83–453) 162 (93–322) 245 (118–491)
Iron saturation (%) 28 ± 13 27 ± 11 28 ± 14 30 ± 15 27 ± 12
TIBC (μg/dL) 238 ± 55 213 ± 63 244 ± 50 250 ± 41 262 ± 48
Calcium (mg/dL) 9.4 ± 0.7 9.4 ± 0.8 9.3 ± 0.6 9.3 ± 0.7 9.7 ± 0.7
Phosphorus (mg/dL) 5.3 ± 1.3 5.3 ± 1.5 5.3 ± 1.2 5.3 ± 1.2 5.2 ± 1.3
iPTH (pg/mL) 305 (174–576) 286 (166–461) 349 (176–604) 315 (185–671) 280 (159–516)
Bicarbonate (mEq/L) 23.8 ± 3.2 24.0 ± 3.1 23.6 ± 3.1 23.6 ± 3.4 24.1 ± 2.9
Creatinine (mg/dL) 6.9 ± 3.5 5.9 ± 3.2 7.4 ± 3.3 7.4 ± 3.5 7.6 ± 4.1
White blood cell (×103/mm3) 8.0 ± 3.2 8.6 ± 3.5 8.0 ± 3.2 7.2 ± 2.7 8.1 ± 3.6
Values for categorical variables are given as numbers and percentages; values for continuous variables, as mean ± standard deviation or median
(interquartile range). Any cells with N ≤ 10 are denoted as such due to patient confidentiality
SI conversion factors: to convert albumin to g/L, multiply by 10; hemoglobin to g/L, multiply by 10; ferritin to pmol/L, multiply by 2.247; TIBC to
μmol/L, multiply by 0.179; calcium to mmol/L, multiply by 0.25; phosphorus to mmol/L, multiply by 0.323; iPTH to ng/L, multiply by 1.0; bicarbonate
to mmol/L, multiply by 1.0; creatinine to μmol/L multiply by 88.4; white blood cell to ×109 /L, multiply by 106
ESRD, end-stage renal disease; CAKUT, congenital anomalies of the kidney and urinary tract; HD, hemodialysis; PD, peritoneal dialysis; CV, central
venous; AVF, arteriovenous fistula; BMI, body mass index; TIBC, total iron binding capacity; iPTH, intact parathyroid hormone
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serum albumin. The hospitalization risk incrementally de-
creased in the range of serum albumin levels between 3.0
and 4.0 g/dL. Considering the high prevalence of mild-to-
moderate hypoalbuminemia in dialysis patients, the incremen-
tal risk for hospitalization in this range should be emphasized.
Our results of increasing risk for hospitalization with hypoal-
buminemia are consistent with previous studies in both chil-
dren and adults [16–18, 22]. In regards to high albumin levels,
some studies have showed a lower hospitalization risk with
higher serum albumin levels over the wide range exceeding
4.0 g/dL [22], while another study showed the hospitalization
risk leveling off in the range of > 4.0 g/dL [23]. Contrary to
these reports, the risk remained beyond 4.0 g/dL in the present
study. In the previous studies for children on maintenance
dialysis, although some focused on serum albumin with hos-
pitalization or mortality using a relatively large dialysis co-
hort, the association of higher serum albumin with these out-
comes is still unclear because high albumin levels have tended
to be regarded as normal albumin, and are usually categorized
within the normal albumin group [17, 18]. In our study, we
used cubic spline functions, which allowed us to evaluate the
potential non-linear association with hospitalization over se-
rum albumin levels extending into the high-normal range [24]
and observed a U-shaped association. In terms of sex differ-
ence, a higher hospitalization frequency for female versus
male patients has been reported in adults with ESRD [25].
Table 2 Hospitalization
frequency and total
hospitalization days across serum
albumin level
Serum albumin level (g/dL)
< 3.5 3.5 to < 4.0 4.0 to < 4.5 ≥ 4.5
Hospitalization frequency 2.7 (2.2–3.2) 1.9 (1.5–2.4) 1.6 (1.3–1.9) 2.7 (1.7–3.6)
Hospitalization days 15.1 (11.2–19.0) 13.0 (7.0–18.9) 8.1 (5.9–10.2) 17.1 (8.7–25.5)
Values are given as incidence rate (95%CI) per patient-year
Fig. 2 Incidence rate ratios for hospitalization frequency with restricted
cubic spline in a unadjusted, b case mix-adjusted, c case mix plus height-
adjusted, and d fully adjusted models. Histogram is the distribution of
baseline serum albumin level. Solid and dotted lines represent incidence
rate ratio and 95% confidence interval, respectively. Incidence rate ratios
were high in both lower and higher albumin levels for all models
(reference: serum albumin 4.0 g/dL)
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However, there were no differences of either serum albumin
or hospitalization frequency betweenmale and female patients
in our pediatric cohort. Instead, whereas low and high serum
albumin were associated with high risk for hospitalization in
males, the hospitalization risk did not change over the ob-
served albumin level in females.
Inadequate growth, particularly short stature, should be
taken into account when evaluating the presence and severity
of PEW among children, in addition to those criteria used
among adult patients, such as serum albumin and BMI [26].
Thus, hypoalbuminemia, short stature, and low BMI could all
correlate with each other as manifestations of PEW among
children. However, we found that baseline serum albumin
was not associated with baseline BMI, although baseline se-
rum albumin was weakly associated with baseline height.
These parameters are not necessarily only for nutritional status
but reflect various comorbid conditions which may induce
inflammatory status and disturb the normal growth hormone
axis [27, 28], and our results support this hypothesis.
Hypoalbuminemia is used as one of the criteria for PEW
in patients with CKD [29], which is consistent with our
findings in the present study. Some markers associated
with nutrition and inflammation, such as hemoglobin and
creatinine [30], had consistent trends with serum albumin
levels at baseline. However, observed trends were not ad-
justed, i.e., important confounders such as age, height, and
erythropoiesis-stimulating agent use were not taken into
account. Moreover, other factors aside from PEW, such
as fluid overload, may also underlie the association be-
tween hypoalbuminemia and high risk for hospitalization.
Although accounting for fluid overload is challenging, the
consistent association in the HD and PD groups might in-
dicate less of an influence of fluid overload given that HD
patients are more likely to have fluid overload compared
with PD patients who often undergo blood draws after a
full night of PD. Even if the effect of fluid overload is
small, we should emphasize that hypoalbuminemia is not
only a surrogate marker of PEW. Hypoalbuminemia
and PEW have been the focus of attention among
nephrologists, while high albumin has not been typically
discussed. Although it remains unclear why we observed
an increasing hospitalization risk with high albumin levels,
high albumin may at least in part reflect unfavorable
conditions resulting in dehydration, induced by difficulty
Fig. 3 Incidence rate ratios for total hospitalization days with restricted
cubic spline in a unadjusted, b case mix-adjusted, c case mix plus height-
adjusted, and d fully adjusted models. Histogram is the distribution of
baseline serum albumin level. Solid and dotted lines represent incidence
rate ratio and 95% confidence interval, respectively. Incidence rate ratios
were high in both lower and higher albumin levels for all models
(reference: serum albumin 4.0 g/dL)
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to estimate dry weight [31] or salt-losing kidney disease,
such as seen in patients with a primary hypoplastic/
dysplastic kidney leading to ESRD [32]. Hospitalization
for high or normal serum albumin also may be due to a
more favorable clinical status, such as the need for an AVF
placement, which may require normal albumin and which
results in hospitalization and operation after achievement
of normal albumin. However, only 1% of total hospitaliza-
tion counts included the date of AVF placement in our
cohort, limiting our ability to evaluate this possibility.
Our results for cause-specific hospitalization may imply
that the risk for hospitalization associated with higher se-
rum albumin could vary depending on the cause of
hospitalization.
Several limitations should be acknowledged. First, due
to the nature of an observational study, we could not
make definitive statements about the causal associations
of serum albumin level and hospitalization. We were also
not able to exclude the possibility of the presence of
unmeasured confounders and residual confounding, in-
cluding unavailable or highly frequent missing data, such
as dietary intake, normalized protein catabolic rate, and
KT/V. We did not have information on active infection at
baseline as well, which should be an exclusion criterion.
Second, this study had limited statistical power due to
small sample size. However, all of the associations be-
tween serum albumin and hospitalization were consistent,
with relatively narrow 95% CIs. Third, we were unable
to take into account urinary protein in the analyses due
to absence of this information. Severe hypoalbuminemia
may be largely attributed to heavy proteinuria rather than to
PEW. The adjustment model including cause of ESRD and the
subg roup ana l y s i s by g l omeru l oneph r i t i s and
nonglomerulonephritis might be an indirect way to take into
account urinary protein. Although the consistent U-shaped
association in both subgroups might indicate less influence
of urinary protein, we are not able to make any
conclusions about the effect of urinary protein. Fourth, the
results for cause-specific hospitalization might be less accu-
rate because of small event numbers and frequently missing
information. These limitations make it difficult to discuss the
pathophysiology for our results. However, our findings
Fig. 4 Hazard ratios for first hospitalization with restricted cubic spline in
a unadjusted, b case mix-adjusted, c case mix plus height-adjusted, and d
fully adjusted models. Histogram is the distribution of baseline serum
albumin level. Solid and dotted lines represent hazard ratio and 95%
confidence interval, respectively. Hazard ratios were high in both lower
and higher albumin levels for all models (reference: serum albumin
4.0 g/dL)
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strongly support the potential of serum albumin for the pre-
diction and risk stratification of hospitalization among chil-
dren with ESRD on dialysis.
In conclusion, serum albumin levels within 1 year of
dialysis initiation showed a U-shaped association with
hospitalization among children with ESRD on dialysis.
Further studies are needed to confirm and elucidate the
association between high serum albumin levels and hos-
pitalization, as well as the gender difference in the
albumin-hospitalization relationship among children.
Fig. 5 Incidence rate ratios for hospitalization frequency with restricted
cubic spline of a males and b females in case mix-adjusted model. Sex
and races were further stratified into c non-African American male and d
non-African American female. Histogram is the distribution of baseline
serum albumin level. Solid and dotted lines represent incidence rate ratio
and 95% confidence interval, respectively
Fig. 6 a Height z score differences and b body mass index (BMI) z score
differences in case mix-adjusted model. Histogram is the distribution of
baseline serum albumin level. Solid and dotted lines represent z score
difference and 95% confidence interval, respectively. Both lower and
higher albumin levels were associated with lower height z score. BMI z
score was slightly low in higher albumin level, whereas there was no
difference in lower albumin level
Pediatr Nephrol (2019) 34:1 –1799 809 1807
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